Merck & Co Inc V.MRK

Primary Symbol: MRK

Healthcare Biotechnology

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

NYSE:MRK - Post by User

Merck & Co Inc

<< Previous

Bullboard Posts

Next >>

Post by FTradingon May 03, 2010 2:10pm

299 Views

Post# 17057019

10,000m drillresults out soon

Mcap 9mil only,very interesting, follow the leaders but do your own DD first

Apr 01/10	Mar 25/10	Pladsen, Thomas John	Direct Ownership	Common Shares	10 - Acquisition in the public market	46,000	.195
Apr 01/10	Mar 23/10	Pladsen, Thomas John	Direct Ownership	Common Shares	10 - Acquisition in the public market	4,000	.195
Feb 26/10	Feb 25/10	McBride, John David	Direct Ownership	Common Shares	10 - Acquisition in the public market	56,500	.210
Feb 26/10	Feb 25/10	McBride, John David	Direct Ownership	Common Shares	10 - Acquisition in the public market	143,500	.205
Jan 28/10	Jan 28/10	McBride, John David	Direct Ownership	Common Shares	00 - Opening Balance-Initial SEDI Report
Dec 10/09	Dec 01/09	Byron, Michael	Control or Direction	Common Shares	10 - Acquisition in the public market	22,000	.220
Dec 10/09	Sep 03/08	Byron, Michael	Control or Direction	Common Shares	00 - Opening Balance-Initial SEDI Report
Nov 25/09	Nov 04/09	Tait, John Graham	Direct Ownership	Common Shares	16 - Acquisition under a prospectus exemption	58,139	.430
Nov 23/09	Nov 16/09	Byron, Michael	Direct Ownership	Common Shares	10 - Acquisition in the public market	50,000	.250
Nov 19/09	Nov 16/09	Pladsen, Thomas John	Direct Ownership	Common Shares	10 - Acquisition in the public market	20,000	.255